In May 2023, SHL Medical and MoonLake Immunotherapeutics collaborated to develop the sonelokimab autoinjector. SHL Medical’s Molly autoinjector technology will be utilized for the clinical and potential commercial supply of MoonLake’s Nanobody sonelokimab. Autoinjectors Market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $1.7 billion […]
